Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Velo-NP** is a modern oral nicotine pouch product containing tobacco-derived, pharmaceutical-grade nicotine but no tobacco leaf or plant matter other than extracted nicotine. It is placed between the gum and cheek to deliver nicotine without combustion or spitting and is designed as a potentially less harmful alternative to traditional smoking and smokeless tobacco[3][4][6]. Clinical and laboratory analyses show that Velo-NP delivers nicotine efficiently, with lower levels of toxicants compared to cigarettes and snus, reduced biomarkers of tobacco-related exposure, and an improved safety profile. Users in trials reported satisfactory nicotine delivery and reduced cigarette consumption over study periods, supporting its use in tobacco harm reduction strategies for adult smokers not ready to quit[1][3][5]. Velo-NP is marketed primarily by British American Tobacco subsidiaries and is part of the broader VELO and nicotine pouch portfolios[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on velo-np.